Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News UCB arthritis treatment approved by EC

UCB arthritis treatment approved by EC

7th October 2009

UCB has announced that its rheumatoid arthritis (RA) therapy Cimzia (certolizumab pegol), has been approved by the European commission (EC) and will now be administered as a subcutaneous injection.

This will be through new pre-filled syringes designed in partnership with OXO Good Grips – an organisation that provides products to make everyday life easier for RA sufferers.

Cimzia is to be used in combination with methotrexate (MTX) for the treatment of moderate to severe active RA in adult patients who are inadequately responsive to disease-modifying antirheumatic drugs alone.

Doctor Iris Loew-Friedrich, chief medical officer of UCB, commented: “Cimzia has been shown to rapidly reduce the rate of progression of joint damage and to improve measurements of patients’ physical function.”

This news comes after UCB signed an agreement with AstraZeneca in September for the joint commercialisation of RA and Crohn’s disease treatment PEGylated anti-TNF alpha drug Cimzia (certolizumab pegol) in Brazil.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.